Macroaxis: Personalized Investing
Simple Personalized Investing

SP 500   1,651   4.84  Index Moved Down -0.29%
GILD AMGN BIIB CELG Iron Farming Aggressive Chemicals 
United States GSPC USD ...  |  Company Directory


Processing
Collecting data for ARQL

ArQule quote and profile

 
 Companies |  Insiders  | Dashboard  
     
2.75
  
STOCK
0.04  Macroaxis: 1.48 Up   1.48%  
Year To Date
1.987.38
Last 1 Month(s)
2.713.08
Trading Day 
2.652.81
May 23 2013 

Diversification Suggestion

Use ArQule to enhance returns of your portfolios. The stock experiences large bullish trend
Analyze ArQule Inc Trend or Check current 30 days ArQule correlation with market (S&P 500)
1 Month Beta 2.6  
Highest Price:  
Lowest Price:  
3.08  
2.71  
April 25 2013 
May 22 2013 
As market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, ArQule will likely underperform.
ArQule Inc Large BetaArQule Inc Beta Legend
ARQL United States Nasdaq
ArQule Inc
Healthcare
Biotechnology
Benchmark S&P 500
http://www.arqule.com
Contact Number: 781. 994. 0300
Currency: USD - US Dollar
Traded on NASDAQ General Markets
    
Current Valuation183.56 M
Shares Outstanding62.86 M
Number of Shares Shorted3.04 M
Revenue33.58 M
 thisGreen ARQL ARQL agains markets  1.48 % Macroaxis: change 1.48 Moved Up  
 
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 United States Russel   0.21 % Macroaxis: 0.21 Moved Up  
 
 United States SP 500   0.29 % Macroaxis: 0.29 Moved Down  
 
 United States NYSE   0.44 % Macroaxis: 0.44 Moved Down  
 
Compare to Competition Get Alpha   Get Advice

ArQule Leadership

Paolo Pucci CEO and Director, MBA
Patrick Zenner Independent Chairman of the Board, MBA
Peter Lawrence President COO
Peter JD President, COO, Principal Financial Officer, General Counsel and Secretary

ArQule Price and Market Media

The median price of ArQule for the period between Tue, Apr 23, 2013 and Thu, May 23, 2013 is 2.85 with a coefficient of variation of 3.76. The daily time series for the period is distributed with a sample standard deviation of 0.11, arithmetic mean of 2.88, and mean deviation of 0.09. The Stock received some media coverage during the period.
ArQule         SP 500
Price Growth (%)
 
1
ArQule Inc. to Present at Needham 12th Annual Healthcare Con...04/24/2013Businesswire News
2
ARQULE INC. ArQule to Report First Quarter 2013 Financial Re...05/02/2013Macroaxis: News
3
NarrowerthanExpected Loss at ArQule05/10/2013Macroaxis: News

ArQule Summary

ArQule Inc [ARQL] is traded on NASDAQ General Markets in USA. It is located in Woburn, MA and employs 97 people. The company currently falls under 'Small-Cap' category with current market capitalization of 178.53 M. ArQule Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 62.86 M outstanding shares of which 3.04 M shares are presently shorted by private and institutional investors with about 8.4 trading days to cover.
ArQule, Inc., a clinicalstage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. more
Past Market
Over 30
Days
0
Out Of
100
 
Chance of
Less
Than
%
 
Follow ArQule with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add ArQule to your reader
 

ArQule Research Report

ArQule vs. Gilead

Correlation analysis and fundamentals comparison between ArQule Inc and Gilead Sciences

ArQule Executives

Peter JD President, COO, Principal Financial Officer, General Counsel and Secretary

ArQule Directors

Susan Kelley Independent Director
William Messenger Independent Director, MBA
Ronald Lindsay Independent Director, Ph.D
Timothy Barabe Independent Director, MBA
Michael Loberg Independent Director, Ph.D

ArQule Management

Robert Esq Chief Corporate Counsel and VP
Robert Weiskopf Principal Accounting Officer, VP of Fin., Corporate Controller and Treasurer
Thomas Chan Chief Scientific Officer, Ph.D

ArQule Fundamentals

Return On Asset vs Total Asset
Number of Shares Shorted vs Current Liabilities
Return On Asset vs Price to Sales
Shares Outstanding vs Current Liabilities

ArQule vs Competition

ArQule vs. Gilead Sciences Inc
ArQule vs. Amgen Inc
ArQule vs. Biogen Idec Inc
ArQule vs. Celgene Corporation
ArQule vs. Regeneron Pharmaceuticals Inc
ArQule vs. Alexion Pharmaceuticals Inc
ArQule vs. Vertex Pharmaceuticals Incorporated
ArQule vs. BioMarin Pharmaceutical Inc
ArQule vs. Illumina Inc
ArQule vs. Onyx Pharmaceuticals Inc

ArQule May 23 2013 Opportunity Range

Downside Deviation2.62
Information Ratio(0.31)
Maximum Drawdown8.87
Value At Risk(3.91)
Potential Upside2.67

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium